Skip to main content
Contact Us
Subscribe
E-Edition
50°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Crispr Therapeutics Ag
(NQ:
CRSP
)
51.83
+0.59 (+1.15%)
Streaming Delayed Price
Updated: 1:01 PM EST, Dec 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Crispr Therapeutics Ag
< Previous
1
2
3
4
5
6
7
8
9
...
30
31
Next >
Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More than 65%
November 30, 2024
Via
The Motley Fool
Cathie Wood Sees Tesla As 'Largest AI Project On Earth' — Here's Why She's Not Worried About Tech Investments
November 29, 2024
Cathie Wood, founder and CEO of ARK Investment Management LLC, defended the future of artificial intelligence investments while highlighting Tesla Inc. as a cornerstone of technological innovation...
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
November 26, 2024
Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts
November 25, 2024
Editas Medicine faces a downgrade to Underperform from BofA, citing competition, limited catalysts, and a reduced price target of $1 from $13.
Via
Benzinga
Down 47% Since March, Is CRISPR Therapeutics Stock a Buy on the Dip?
November 24, 2024
Via
The Motley Fool
Where Will CRISPR Therapeutics Be in 3 Years?
November 15, 2024
Via
The Motley Fool
3 Monster Stocks in the Making
November 23, 2024
Via
The Motley Fool
Deciphering Disruption: Inside Cathie Wood's Latest Plays
November 16, 2024
Cathie Wood's recent stock market activity offers a glimpse into her evolving investment strategy and the potential of disruptive technologies.
Via
MarketBeat
Topics
Artificial Intelligence
ETFs
Exposures
Artificial Intelligence
2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More
November 16, 2024
Via
The Motley Fool
3 Unstoppable Growth Stocks I'm Loading $25,000 Each Into by 2029
November 13, 2024
These three emerging technology leaders are pioneering quantum computing, gene editing, and electric aviation.
Via
The Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
November 08, 2024
The rock star fund investor made a lot of big moves on Thursday.
Via
The Motley Fool
Smaller Cap Biotechs Are In Season: How Are We Doing?
November 07, 2024
SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range.
Via
Talk Markets
3 Companies Building Tomorrow's Game-Changing Technologies
November 05, 2024
These pioneering companies are transforming delivery, medicine, and space access--potentially creating massive opportunities for early investors.
Via
The Motley Fool
Thinking of Buying CRISPR Therapeutics Stock? Watch These 2 Key Numbers
November 02, 2024
It won't be able to be profitable without hitting its targets for both of these figures.
Via
The Motley Fool
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500
October 31, 2024
The Ark Innovation and Ark Genomic ETFs turn ten years old. A look at the annual returns and current top holdings.
Via
Benzinga
Topics
ETFs
Stocks
Exposures
US Equities
12 High-Growth Stocks That Could Deliver Parabolic Returns
October 28, 2024
These 12 innovative companies could deliver exponential returns over the next quarter century.
Via
The Motley Fool
The Ultimate Biotech Stock to Buy With $50 Right Now
October 26, 2024
This company might be worth far more than many realize.
Via
The Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
October 22, 2024
The aggressive growth icon kicked off the new trading week by buying some of her favorite stocks.
Via
The Motley Fool
Why We Buy Stocks
October 21, 2024
Is fear of missing out (FOMO) controlling your portfolio?
Via
The Motley Fool
3 Bargain Stocks to Buy in a Market That's Priced for Perfection
October 19, 2024
Yes, bargains can still be found in the stock market.
Via
The Motley Fool
Why I Keep Buying These 14 Incredible Growth Stocks
October 16, 2024
This diverse set of growth stocks offers tremendous opportunities in the fields of AI, space, biotech, and emerging industries.
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Is CRISPR Therapeutics Stock a Buy?
October 13, 2024
The markets this biotech is looking to enter could be extremely lucrative.
Via
The Motley Fool
2 Biotech Stocks That Are Screaming Buys This Month
October 12, 2024
They won't remain southbound forever.
Via
The Motley Fool
This Healthcare Growth Stock Could Be a Steal of a Deal Right Now
October 05, 2024
CRISPR Therapeutics is trading around multiyear lows.
Via
The Motley Fool
These 2 Healthcare Stocks With Big Catalysts on the Horizon Can Make You Richer
October 02, 2024
Market-beating returns could be on the way for patient investors in these two up-and-coming healthcare growth stocks.
Via
The Motley Fool
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.
September 26, 2024
Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths.
Via
Investor's Business Daily
3 Dirt Cheap Stocks to Buy Right Now
September 21, 2024
Bargain hunters should love these great stocks.
Via
The Motley Fool
Down 21% This Year, Is CRISPR Therapeutics Stock Still a Buy?
September 19, 2024
There's a lot of growth on the way, and soon.
Via
The Motley Fool
1 Biotech Stock Down 62% to Buy and Hold
September 12, 2024
It's an excellent opportunity to buy shares of what could become a biotech giant on the dip.
Via
The Motley Fool
3 No-Brainer Biotech Stocks to Buy With $200 Right Now
September 12, 2024
An investment in these players today could score a big win down the road.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
30
31
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.